CoChat

D-Cycloserine in Neuropsychiatric Diseases: A Systematic Review

Open access
Schade, Sebastian, Paulus, Walter · 2016 · International Journal of Neuropsychopharmacology

The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.

Abstract

D-Cycloserine, known from tuberculosis therapy, has been widely introduced to neuropsychiatric studies, since its central active mechanism as a partial NMDA-agonist has been found. In this review, we evaluate its therapeutic potential in neuropsychological disorders and discuss its pitfalls in terms of dosing and application frequency as well as its safety in low-dose therapy. Therefore, we identified 91 clinical trials by performing a Medline search. We demonstrate in part preliminary but increasing evidence that D-cycloserine may be effective in various psychiatric diseases, including schizophrenia, anxiety disorders, addiction, eating disorders, major depression, and autism as well as in neurological diseases, including dementia, Alzheimer's disease, and spinocerebellar degeneration. D-Cycloserine in low-dose therapy is safe, but there is still a need for new drugs with higher specificity to the different N-methyl-D-aspartate-receptor subunits.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ijnp/pyv102

Cites

79 of 79 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Schematic structure of the NMDA receptor. The NMDA receptor consists of 2 subunits (NR1 and NR2A, NR2B or NR2C). The NR2 subunits hold the glutamate binding site (GluBS), where the main agonist glutamate (Glu) binds. The NR1 subunit holds the glycine binding site (GlyBS), where the natural co-agonist glycine (Gly) or the partial agonist D-Cycloserine (DCS) bind. For further agonists and antagonists of the GlyBS see Table 1. For further details on the structure of the NMDA receptor see Dravid et al. (2010).
Figure 1. Schematic structure of the NMDA receptor. The NMDA receptor consists of 2 subunits (NR1 and NR2A, NR2B or NR2C). The NR2 subunits hold the glutamate binding site (GluBS), where the main agonist glutamate (Glu) binds. The NR1 subunit holds the glycine binding site (GlyBS), where the natural co-agonist glycine (Gly) or the partial agonist D-Cycloserine (DCS) bind. For further agonists and antagonists of the GlyBS see Table 1. For further details on the structure of the NMDA receptor see Dravid et al. (2010).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 135

Metadata

Authors
Schade, S., & Paulus, W.
Affiliations
Universitätsmedizin Göttingen (DE)
Corresponding author
Schade, Sebastian
Venue
International Journal of Neuropsychopharmacology
Published
2015-09-12
Volume
19
Issue
4
Pages
pyv102
ISSN
  • 1461-1457 (ISSN-L)
  • 1469-5111
OpenAlex
W2336203720
Cited by
135
References
79
Citations by year
2026: 13 · 2025: 23 · 2024: 10 · 2023: 18 · 2022: 10 · 2021: 13 · 2020: 11 · 2019: 14 · 2018: 8 · 2017: 7 · 2016: 7 · 2015: 1
FWCI
0.96
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • The International Journal of Neuropsychopharmacology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, cc-by)
  • HighWire Press Open Archive (submittedVersion)
  • GRO (submittedVersion, cc-by)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords
D-cycloserine, NMDA receptor partial agonist, schizophrenia, anxiety disorders, addiction, eating disorders, major depressive disorder, autism spectrum disorder, dementia, Alzheimer's disease, spinocerebellar degeneration, dosing and administration, neuropsychiatric disorders
MeSH terms
Animals, Mental Disorders, Cycloserine, Humans, Nervous System Diseases, Psychotropic Drugs, Receptors, N-Methyl-D-Aspartate, Excitatory Amino Acid Agonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.